Dianne Angus
Net worth: 438 455 $ as of 2026-09-29
Net worth: 438 455 $ as of 2026-09-29
Ms. Dianne Angus is an Independent Non-Executive Director at Cyclopharm Ltd., an Independent Non-Executive Director at Neuren Pharmaceuticals Ltd., a Council Member at Deakin University and a Member at Australian Institute of Co. Directors.
She is on the Board of Directors at Cyclopharm Ltd. and Neuren Pharmaceuticals Ltd. Ms. Angus was previously employed as an Independent Non-Executive Chairman by Argenica Therapeutics Ltd., an Independent Non-Executive Director by Imagion Biosystems Ltd., a Chief Operating Officer by Alterity Therapeutics Ltd., and a Manager-Joint Venture Alliance by Calgene Pacific Ltd. She also served on the board at Dianne Angus & Associates Pty Ltd. She received her undergraduate degree from the University of Melbourne and a graduate degree from Monash University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-15 | 30,000 ( 0.02% ) | 424 725 $ | 2026-09-29 | |
CYCLOPHARM LIMITED 0.03% | 2026-03-11 | 43,375 ( 0.03% ) | 13 730 $ | 2026-09-29 |
| Companies | Position | Start |
|---|---|---|
| NEUREN PHARMACEUTICALS LIMITED | Director/Board Member | 2018-07-04 |
| CYCLOPHARM LIMITED | Director/Board Member | 2021-08-09 |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Promotes governance and develops leadership skills | Corporate Officer/Principal | - |
Deakin University
Deakin University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
| Companies | Position | End |
|---|---|---|
| ARGENICA THERAPEUTICS LIMITED | Chairman | 2025-12-30 |
| IMAGION BIOSYSTEMS LIMITED | Director/Board Member | 2024-05-02 |
Dianne Angus & Associates Pty Ltd. | Director/Board Member | 2002-07-31 |
Florigene Ltd.
Florigene Ltd. BiotechnologyHealth Technology Provides genetic modification technology to bridge genetic gaps and deliver improvements to flower species | Corporate Officer/Principal | 1999-12-31 |
| ALTERITY THERAPEUTICS LIMITED | Chief Operating Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 11 |
|---|---|
Neuren Pharmaceuticals Ltd.
Neuren Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Manufactures drugs for neurological disorders | Health Technology |
Cyclopharm Ltd.
Cyclopharm Ltd. Medical SpecialtiesHealth Technology Manufactures and sells medical health care equipments | Health Technology |
Alterity Therapeutics Ltd.
Alterity Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic drugs | Health Technology |
University of Melbourne
University of Melbourne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Florigene Ltd.
Florigene Ltd. BiotechnologyHealth Technology Provides genetic modification technology to bridge genetic gaps and deliver improvements to flower species | Health Technology |
Monash University
Monash University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Deakin University
Deakin University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Promotes governance and develops leadership skills | Commercial Services |
Dianne Angus & Associates Pty Ltd. | |
Imagion Biosystems Ltd.
Imagion Biosystems Ltd. Medical SpecialtiesHealth Technology Develops medical devices | Health Technology |
Argenica Therapeutics Ltd.
Argenica Therapeutics Ltd. BiotechnologyHealth Technology Develops novel neuro protective therapeutics to reduce brain damage | Health Technology |
Select your edition
All financial news and data tailored to specific country editions